Disease modification in osteoarthritis: Are drugs the answer?

Arthritis and Rheumatism

Volumn 52, Issue 7, 2005, Pages 1956-1959

  Dieppe, Paul ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; GELATINASE; GLUCOSAMINE; HYALURONIC ACID; PROCOLLAGENASE; PROTEINASE INHIBITOR;

CARTILAGE DEGENERATION; DISEASE COURSE; DRUG EFFECT; EDITORIAL; HIGH RISK PATIENT; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE REGENERATION;

ANIMALS; ANTHRAQUINONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CARTILAGE, ARTICULAR; COLLAGENASES; DISEASE MODELS, ANIMAL; DOXYCYCLINE; ENZYME PRECURSORS; HUMANS; OSTEOARTHRITIS;

EID: 22244441491     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21124     Document Type: Editorial

References (25)

1. Dieppe PA, Brandt KD. What is important in treating osteoarthritis? Whom should we treat and how should we treat them? Rheum Dis Clin North Am 2003;29:687-716.
2. Scott D, Smith C, Lohmander S, Chard J. Osteoarthritis. In: Clinical evidence. London: BMJ Publications; 2005. URL: www. clinicalevidence.com.
3. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25.
4. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26.
5. Smith GN Jr, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996;39:235-44.
6. Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O'Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992;35:1150-9.
7. Yu LP, Smith GN, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991;18:1450-2.
8. Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis 1994;53:565-8.
9. Dieppe P, Cushnaghan J, Shepstone L. The Bristol OA 500 Study: progression of osteoarthritis (OA) over three years and the relationship between clinical and radiographic changes at the knee joint. Osteoarthritis Cartilage 1997;5:87-97.
10. Creamer P. Current perspectives on the clinical presentation of joint pain in human OA. In: Osteoarthritic joint pain: Novartis symposium 260. London: John Wiley and Sons; 2004. p. 64-78.
11. Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers [review]. Curr Opin Investig Drugs 2000;1:169-72.
12. Homes SG, Still K, Buttle DJ, Bishop NJ, Grabowski PS. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors. Bone 2004;35:471-8.
13. Rogers J, Shepstone L, Dieppe P. Is osteoarthritis a systemic disorder of bone? Arthritis Rheum 2004;50:452-7.
14. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, for the ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 2001;44:2539-47.
15. Felson D. Chair's introduction. In: Osteoarthritic joint pain: Novartis symposium 260. London: John Wiley and Sons; 2004. p. 1-3.
16. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
17. Mazzuca SA, Brandt KD, Buckwalter KA, Lequesne M. Pitfalls in the accurate measurement of joint space narrowing in semiflexed, anteroposterior radiographic imaging of the knee. Arthritis Rheum 2004;50:2508-15.
18. Chard J, Dieppe P. Glucosamine for osteoarthritis: magic, hype or confusion? BMJ 2001;322:1439-40.
19. Koshino T, Wada S, Ara Y, Saito T. Regeneration of degenerated articular cartilage after high tibial valgus osteotomy for medial compartment osteoarthritis of the knee. Knee 2003;10:229-36.
20. Marijnissen AC, van Roermund PM, van Melkebeek J, Schenk W, Verbeut AJ, Bijlsma JW, et al. Clinical benefit of joint distraction in the treatment of severe osteoarthritis of the ankle: proof of concept in an open prospective study and in a randomized controlled study. Arthritis Rheum 2002;46: 2893-902.
21. Toda Y, Tsukimura N. A six-month followup of a randomized trial comparing the efficacy of a lateral-wedge insole with subtalar strapping and an in-shoe lateral-wedge insole in patients with varus deformity osteoarthritis of the knee. Arthritis Rheum 2004; 50:3129-36.
22. Hunziker EB. Articular cartilage repair: basic science and clinical progress: a review of the current status and prospects. Osteoarthritis Cartilage 2002;10:432-63.
23. Dieppe P, Bartlett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms: the example of nonsteroidal antiinflammatory drugs. BMJ 2004;329:31-4.
24. Chard JA, Tallon D, Dieppe P. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis 2000;59:414-8.
25. Hadler NM. The last well person: how to stay well despite the health-care system. Quebec City: McGill-Queen's University Press; 2004.